Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus (Q33658772)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus (English)

1 reference

Europe PubMed Central

28 July 2017

type-1 diabetes

0 references

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Tim Heise

1

1 reference

Europe PubMed Central

28 July 2017

Kirstine Stender-Petersen

2

1 reference

Europe PubMed Central

28 July 2017

Ulrike Hövelmann

3

1 reference

Europe PubMed Central

28 July 2017

Jacob Bonde Jacobsen

4

1 reference

Europe PubMed Central

28 July 2017

Leszek Nosek

5

1 reference

Europe PubMed Central

28 July 2017

Eric Zijlstra

6

1 reference

Europe PubMed Central

28 July 2017

Hanne Haahr

7

1 reference

Europe PubMed Central

28 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 November 2016

1 reference

Europe PubMed Central

28 July 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

28 July 2017

56

1 reference

Europe PubMed Central

28 July 2017

649-660

1 reference

Europe PubMed Central

28 July 2017

6

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1007/s40262-016-0473-5

0 references

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Ultrafast-acting insulins: state of the art

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Insulin analogues: an example of applied medical science

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Getting closer to physiologic insulin secretion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin-stimulated glucose disposal during euglycemic clamp studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5425492

21 June 2018

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Injection-meal interval: recommendations of diabetologists and how patients handle it.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40262-016-0473-5

21 January 2018

Dose-response relationship of insulin glulisine in subjects with type 1 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of time to onset and rate of action of insulin products: importance and new approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The variability in the action of unmodified insulin is more dependent on changes in tissue insulin sensitivity than on insulin absorption

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Insulin aspart has a shorter duration of action than human insulin over a wide dose-range

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of Splanchnic and Peripheral Glucose Uptake by Insulin and Hyperglycemia in Man

1 reference

https://pubmed.ncbi.nlm.nih.gov/27878566

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-016-0473-5

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33658772&oldid=2143950935"